Investigating a new imaging technique for measuring glycolysis in glioblastoma tumors
Biologic Association Between Metabolic MR-PET and Tissue Measures of Glycolysis in Brain Tumors Visualization, Quantitation, and Targeting of Infiltrating Glioblastoma Cells With pH Sensitive Amine Chemical Exchange Saturation Transfer Magnetic Resonance Imaging-KL2TR001882
This study is testing a new imaging method to see if it can help doctors measure how energy is used in glioblastoma tumors and find hidden cancer cells that are hard to see.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06059690 on ClinicalTrials.gov |
What this trial studies
This project aims to validate a novel combined MRI and PET imaging technique as a biomarker for glycolysis in brain tumors, specifically glioblastoma multiforme. Patients scheduled for tumor resection will undergo FDG-PET scans and investigational MR imaging sequences to calculate a 'glycolytic index'. The study will correlate imaging measurements with tissue pH, RNA expression, protein expression, and bioenergetics of key glycolytic enzymes obtained from biopsied tumor tissue. The goal is to determine if metabolic differences identified through imaging can help detect infiltrating non-enhancing tumor cells.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with newly diagnosed or recurrent glioblastoma who are clinically indicated for resective surgery.
Not a fit: Patients who cannot undergo MRI or FDG PET scans due to safety concerns or severe claustrophobia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable imaging biomarker for assessing glycolysis in glioblastoma, potentially improving treatment strategies.
How similar studies have performed: While the approach is innovative, similar imaging techniques have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 * Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery Exclusion Criteria: * Patients who cannot obtain an MRI or FDG PET scan with contrast * Those with ferromagnetic implanted devices that might produce a safety hazard (e.g. infusion pumps, pace makers, aneurysm clips, etc.) will be excluded from the study along with subjects with severe claustrophobia or who have severely compromised renal function (GFR \< 30).
Where this trial is running
Los Angeles, California
- University of California at Los Angeles — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Benjamin Ellingson, PhD — University of California at Los Angeles
- Study coordinator: Raksha Nagaraj
- Email: RNagaraj@mednet.ucla.edu
- Phone: 310-794-8995
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.